Figures & data
Table 1. QHES grading system for cost-effectiveness studies (Chiou et al., 2003)Citation[7].
Table 2. Description of cost-effectiveness studies included in the review.
Table 3. Summary of methods and base-case results of studies included in the review.
Table 4. Results of quality assessment using QHES grading systemCitation[6].
Chiou CF, Hay JW, Wallace JF, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care 2003; 41: 32–44 Guest JF, Abegunde D, Ruiz FJ. Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria. Clin Drug Invest 2004; 24: 305–321 Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon α–2b plus ribavirin versus interferon α–2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425–432 Buti M, Medina M, Casado MA, et al. A cost-effectiveness analysis of peginterferon alfa–2b plus ribavirin for the treatment of naïve patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17: 687–694 Simon K, Gladysz A, Rotter K, et al. Cost effectiveness of replacing recombinated interferon α–2b with its pegylated form in combination with ribavirin for the therapy of chronic HCV infection in Poland. Adv Clin Exp Med 2006; 15: 453–462 Faber A, van Agthoven M, Kalverdijk LJ, et al. Long-acting methylphenidate – OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. CNS Drugs 2008; 22: 157–170 Edwards NC, Locklear JC, Rupnow MFT, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005; 23(Suppl 1)75–89 Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in Health and Medicine. Oxford University Press, New York 1996